Inhibiting the Jumonji Family: A Potential New Clinical Approach to Targeting Aberrant Epigenetic Mechanisms

Click to increase image sizeClick to decrease image size

Financial & competing interests disclosure

This work was partly funded by the NIH (R01 CA125269 to ED Martinez; R21 AI116222 to ED Martinez), by the Friends of the Cancer Center, by The Welch Foundation (I-1878 to ED Martinez), and by CPRIT (RP120717). Funding was also provided by the Texas Specialized Program of Research Excellence in Lung Cancer (P50CA70907) from the National Cancer Institute, USA. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

This work was partly funded by the NIH (R01 CA125269 to ED Martinez; R21 AI116222 to ED Martinez), by the Friends of the Cancer Center, by The Welch Foundation (I-18 78 to ED Martinez), and by CPRIT (RP120717). Funding was also provided by the Texas Specialized Program of Research Excellence in Lung Cancer (P50CA70907) from the National Cancer Institute, USA. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.